NRGN and Alzheimer disease: Furthermore, differences in the interaction of tauP301L with members of the calcium-calmodulin signalling pathway were identified, most notably, a loss in association with the candidate AD biomarker neurogranin matched by a parallel increase in the extracellular levels of neurogranin.